0.4672
price up icon8.40%   0.0362
pre-market  Vorhandelsmarkt:  .46   -0.0072   -1.54%
loading
Schlusskurs vom Vortag:
$0.431
Offen:
$0.451
24-Stunden-Volumen:
501.42K
Relative Volume:
0.93
Marktkapitalisierung:
$18.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
-0.1512
EPS:
-3.09
Netto-Cashflow:
$-101.06M
1W Leistung:
+17.89%
1M Leistung:
+54.19%
6M Leistung:
-15.01%
1J Leistung:
-85.58%
1-Tages-Spanne:
Value
$0.451
$0.4849
1-Wochen-Bereich:
Value
$0.365
$0.4849
52-Wochen-Spanne:
Value
$0.2195
$3.67

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Firmenname
Athira Pharma Inc
Name
Telefon
(425) 620-8501
Name
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Mitarbeiter
26
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
ATHA's Discussions on Twitter

Vergleichen Sie ATHA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATHA
Athira Pharma Inc
0.4672 15.47M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-19 Herabstufung Mizuho Outperform → Neutral
2024-09-04 Herabstufung BTIG Research Buy → Neutral
2024-09-04 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2024-09-04 Herabstufung Rodman & Renshaw Buy → Neutral
2024-08-19 Eingeleitet Rodman & Renshaw Buy
2022-10-17 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2022-07-07 Eingeleitet Mizuho Buy
2022-06-23 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2022-06-23 Herabstufung Jefferies Buy → Hold
2022-06-23 Herabstufung Stifel Buy → Hold
2022-05-10 Eingeleitet BTIG Research Buy
2022-04-21 Eingeleitet Berenberg Buy
2021-12-15 Eingeleitet Goldman Neutral
2020-10-13 Eingeleitet Goldman Buy
2020-10-13 Eingeleitet JMP Securities Mkt Outperform
2020-10-13 Eingeleitet Jefferies Buy
2020-10-13 Eingeleitet Stifel Buy
Alle ansehen

Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten

pulisher
03:37 AM

Athira Pharma (NASDAQ:ATHA) Trading Up 8.4% – Here’s Why - Defense World

03:37 AM
pulisher
Jul 22, 2025

Is Athira Pharma Inc. a good long term investmentMarket-crushing stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about Athira Pharma Inc. stockGame-changing capital returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What drives Athira Pharma Inc. stock priceRecord-breaking capital gains - Autocar Professional

Jul 21, 2025
pulisher
Jul 17, 2025

Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView

Jul 17, 2025
pulisher
Jul 16, 2025

Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Why Athira Pharma Inc. stock attracts strong analyst attentionHigh Accuracy Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Athira Pharma Inc. stock performs during market volatilityDouble Profit With Half Risk - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Athira Pharma Inc. stock price move sharplyTop Gaining Low Risk Assets - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 10, 2025
pulisher
Jun 25, 2025

Is Athira Pharma, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 05, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire

Jun 04, 2025
pulisher
Jun 03, 2025

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 03, 2025
pulisher
Jun 02, 2025

Athira Pharma Holds Annual Stockholders Meeting - TipRanks

Jun 02, 2025
pulisher
Jun 01, 2025

Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 01, 2025
pulisher
May 27, 2025

This Athira Pharma Insider Increased Their Holding By 111% Last Year - Yahoo Finance

May 27, 2025
pulisher
May 20, 2025

Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com

May 20, 2025
pulisher
May 15, 2025

Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Athira Pharma Reports Reduced Losses and Strategic Focus - MSN

May 14, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan

May 13, 2025
pulisher
May 10, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times

May 09, 2025
pulisher
May 08, 2025

Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World

May 08, 2025
pulisher
May 07, 2025

Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st

May 07, 2025
pulisher
May 06, 2025

Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World

May 06, 2025
pulisher
Apr 29, 2025

Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Apr 29, 2025
pulisher
Apr 24, 2025

ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 17, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com India

Apr 17, 2025
pulisher
Apr 16, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia

Apr 16, 2025

Finanzdaten der Athira Pharma Inc-Aktie (ATHA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):